InsiderTrades.com logo
Nicole Sweeny net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Nicole Sweeny Biography and Net Worth

Insider of KalVista Pharmaceuticals

Nicole has more than 20 years of commercial strategy and leadership experience and has launched several approved products for rare diseases, including HAE. She previously was US Franchise Head of the Hereditary Angioedema team at Takeda Pharmaceuticals where she was responsible for the US launch of the market-leading HAE prophylaxis treatment Takhzyro®. Before Takeda, Nicole held positions of increasing responsibility at Shire Pharmaceuticals in marketing, sales and product strategy across HAE treatments including Cinryze®, Firazyr® and Kalbitor®, as well serving as the Global Product Strategy Lead for Hemophilia.

Most recently, she served as Chief Commercial Officer at Praxis Precision Medicines, where she led commercial strategy and built capabilities to support global launches for both common and rare CNS conditions. Nicole received a BS in Marketing from the Carroll School of Management at Boston College.

What is Nicole Sweeny's net worth?

The estimated net worth of Nicole Sweeny is at least $1.60 million as of May 26th, 2026. Sweeny owns 59,291 shares of KalVista Pharmaceuticals stock worth more than $1,600,857 as of July 6th. This net worth estimate does not reflect any other assets that Sweeny may own. Learn More about Nicole Sweeny's net worth.

How do I contact Nicole Sweeny?

The corporate mailing address for Sweeny and other KalVista Pharmaceuticals executives is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. KalVista Pharmaceuticals can also be reached via phone at 857-999-0075 and via email at [email protected]. Learn More on Nicole Sweeny's contact information.

Has Nicole Sweeny been buying or selling shares of KalVista Pharmaceuticals?

Nicole Sweeny has not been actively trading shares of KalVista Pharmaceuticals during the last quarter. Most recently, Nicole Sweeny sold 1,489 shares of the business's stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $26.78, for a transaction totalling $39,875.42. Following the completion of the sale, the insider now directly owns 59,291 shares of the company's stock, valued at $1,587,812.98. Learn More on Nicole Sweeny's trading history.

Who are KalVista Pharmaceuticals' active insiders?

KalVista Pharmaceuticals' insider roster includes Paul Audhya (Insider), Thomas Crockett (CEO), Edward Feener (Insider), Andreas Maetzel (SVP), Benjamin Palleiko (Chief Executive Officer and Director), Brian Piekos (CFO), Michael Smith (VP), Nicole Sweeny (Insider), and Christopher Yea (Insider). Learn More on KalVista Pharmaceuticals' active insiders.

Are insiders buying or selling shares of KalVista Pharmaceuticals?

During the last year, insiders at the specialty pharmaceutical company sold shares 33 times. They sold a total of 379,144 shares worth more than $6,508,682.21. The most recent insider tranaction occured on May, 26th when insider Nicole Sweeny sold 1,489 shares worth more than $39,875.42. Insiders at KalVista Pharmaceuticals own 4.3% of the company. Learn More about insider trades at KalVista Pharmaceuticals.

Information on this page was last updated on 5/26/2026.

Nicole Sweeny Insider Trading History at KalVista Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/26/2026Sell1,489$26.78$39,875.4259,291View SEC Filing Icon  
5/22/2026Sell1,861$26.78$49,837.5855,780View SEC Filing Icon  
4/17/2026Sell1,862$20.22$37,649.6451,391View SEC Filing Icon  
2/23/2026Sell3,975$15.57$61,890.7547,003View SEC Filing Icon  
8/25/2025Sell1,480$13.42$19,861.6032,291View SEC Filing Icon  
8/22/2025Sell1,864$13.22$24,642.0828,771View SEC Filing Icon  
See Full Table

Nicole Sweeny Buying and Selling Activity at KalVista Pharmaceuticals

This chart shows Nicole Sweeny's buying and selling at KalVista Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

KalVista Pharmaceuticals Company Overview

KalVista Pharmaceuticals logo
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $27.00
Low: $27.00
High: $27.00

50 Day Range

MA: $26.43
Low: $19.16
High: $27.00

2 Week Range

Now: $27.00
Low: $9.83
High: $27.00

Volume

N/A

Average Volume

3,070,118 shs

Market Capitalization

$1.44 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A